Nov 6 (Reuters) -
EPS CO LTD
PARENT-ONLY FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to Six months to
Sep 30, 2009 Sep 30, 2008 Sep 30, 2010 Mar 31, 2010
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULTS FORECASTS H1 FORECASTS
Sales 15.40 13.11 16.77 8.16
(+17.5 pct) (+20.4 pct) (+8.9%) (+9.8%)
Operating 3.35 2.44 3.24 1.52
(+37.1 pct) (+23.1 pct) (-3.4%) (0.0%)
Recurring 3.51 2.61 3.34 1.59
(+34.3 pct) (+24.0 pct) (-4.7%) (-2.4%)
Net 1.58 1.36 1.93 908 mln
(+16.4 pct) (+26.1 pct) (+22.1%) (+101.2%)
EPS Y17,715.12 Y15,220.18 Y21,635.32 Y10,159.91
EPS Y15,203.86
Annual div Y6,000.00 Y5,400.00 Y6,600.00
-Q2 div Y2,800.00 Y2,400.00 Y3,200.00
-Q4 div Y3,200.00 Y3,000.00 Y3,400.00
NOTE - EPS Co Ltd conducts clinical trials for pharmaceutical makers.
If there is no Q1 or Q3 dividend, Q2 will in most cases
correspond to the first-half dividend and Q4 to the second-half
dividend announced before a new corporate law in 2006 allowed
companies to pay and report dividends on a quarterly basis.
For latest earnings estimates made by Toyo Keizai, please
double click on 4282.TK1.
